TauRx exists to solve one of the world’s biggest challenges – beating Alzheimer’s and other degenerative brain diseases via a completely new approach Read more

We combine pioneering research and drug development Read more

Our protein aggregation inhibitors aim to halt disease progression by targeting the underlying pathology of dementia Read more

Protein aggregation inhibitor LMTX® is a patented novel chemical entity currently in development for the prevention of Alzheimer’s and bvFTD Read more

LMTX® is now in Phase 3 clinical trials taking place in 20 countries and involving over 1,900 patients Read more

Pioneering Science

The tau tangle pathway is a key driver of Alzheimer’s disease leading to loss of neuronal function, spread of pathology and clinical symptoms. View

Pioneering Science

Alzheimer's Innovations

TauRx’s tau aggregation inhibitors are the outcome of nearly 30 years of research, preclinical and clinical investigations. View

Alzheimer's Innovations

Clinical
Trials

Initial results from Phase 3 trials currently underway with LMTX®, TauRx’s second-generation tau aggregation inhibitor, are expected in Q3 2016.

View

Clinical<br/>Trials